News Release

Durability of response to SARS-CoV-2 BioNTech-Pfizer vaccination in patients on active anticancer treatment

JAMA Oncology

Peer-Reviewed Publication

JAMA Network

What The Study Did: Researchers describe the antispike IgG antibody response to the SARS-CoV-2 BNT162b2 messenger RNA (mRNA) vaccine (BioNTech-Pfizer) in patients with cancer compared with healthy controls about four months after the second vaccine dose.

Authors: Salomon M. Stemmer, M.D., of the Rabin Medical Center, Beilinson Hospital in Petah Tikva, Israel, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link


Editor’s Note: The article includes conflicts of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.